Price Competition To Procrit Is Beginning To Stabilize, J&J Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Recent price increases for both Procrit and Amgen’s Aranesp indicate the discount war may be over for now, J&J says. The company remains positive about the impact of the 2005 changes to Medicare Part B drug reimbursement on Procrit’s positioning within the EPO market.
You may also be interested in...
J&J Expects Procrit Stability Under Medicare Average Sales Price Model
Despite volume gains, Procrit sales slumped 12% over the year due to pricing pressue. The growing EPO market coupled with pricing stability under Medicare Part B offers an opportunity for Procrit growth in 2005, Johnson & Johnson Worldwide Chairman Poon says.
J&J Expects Procrit Stability Under Medicare Average Sales Price Model
Despite volume gains, Procrit sales slumped 12% over the year due to pricing pressue. The growing EPO market coupled with pricing stability under Medicare Part B offers an opportunity for Procrit growth in 2005, Johnson & Johnson Worldwide Chairman Poon says.
Procrit Sales Slump Continues Due To 10% Year-Over-Year Price Decline
Conditions, however, are more favorable than in previous quarters due to a June price increase on the EPO brand, J&J says. With prices locked into 12-month contracts, it may take awhile for J&J to reap the full benefit of the price increase.